Clinical Trial Database

CICC Clinical Trials

Current Protocols: updated 03/01/11

Central Scheduling: 317-356-2422

Breast
Randomized Phase II Trial of Letrozole with or without Dasatinib as First and Second-Line Treatment for Hormone Receptor-Positive, HER2-Negative Post-Menopausal Breast Cancer that is Unresectable, Locally Recurrent or Metastatic breast cancer
-
A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer (NSABP B-46-I)
-
A Phase 2, Open-Label Study of EZN-2208 (PEG-SN38) in Patients with Previously Treated Metastatic Breast Cancer: prior AT- no more than 2 prior chemo regimens : Prior ATX- no more than 4 prior chemo- HOLD
-
Phase II Trial of Ixabepilone plus Carboplatin in Patients with Metastatic Breast Cancer HER2neg / TNBC only arm accruing
-
A Randomized Double Blind Placebo-Controlled Trial of Neratinib (HKI-272) Following Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer
-
A randomized phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel, as first line therapy in women with HER2-positive locally advanced or MBC
-
A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors:Breast cancer that is one of the following subtypes: estrogen receptor positive breast cancer, or inflammatory breast cancer, regardless of the hormonal receptor status: Up to three prior standard treatment regimens
-
An Open-Label, Expanded Access Protocol of Iniparib in Combination with Gemcitabine/Carboplatin in Patients with ER-, PR-, and HER2-Negative MBC
-
A Phase 2, Multicenter, Single-Arm, Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer
-
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer  B39 RTOG 0413
-
A Phase III Clinical Trial Comparing Trastuzumab Given Concurently with Radiation and Radiation Alone for Women with Her2-Postive Ductal Carcinoma In Situ (DCIS) Resected by Lumpectomy NSABP B43 RTOG

Lung/NSCLC
Randomized, Open-Label, Phase 3 Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer  PK ONLY to enroll
-
An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination with Platinum-based Chemotherapy versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients with Recurrent or Advanced NSCLC
-
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects with Locally Advanced or Metastatic, Non-Squamous, NSCLC
-
A randomized, open-label, Phase II, 2-arm multi-center trial comparing maintenance therapy with pazopanib or pemetrexed in non-progressing subjects with metastatic stage IVA and IVB non-squamous NSCLC after induction therapy with carboplatin or cisplatin plus pemetrexed
-
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy
-
A RANDOMIZED PHASE III COMPARISON OF STANDARD- DOSE (60 Gy) VERSUS HIGHDOSE (74 Gy) CONFORMAL RADIOTHERAPY WITH CONCURRENT AND CONSOLIDATION CARBOPLATIN/PACLITAXEL +/- CETUXIMAB (IND# 103444)IN PATIENTS WITH STAGE IIIA/IIIB NON-SMALL CELL LUNG CANCER  RTOG 0617

Prostate
A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone with or without Lenalidomide in Subjects with Castrate-Resistant Prostate Cancer (CRPC)
-
A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
-
Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy
-
A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy In Prostate Cancer Patients With A Rising Psa After Radical Prostatectomy (RTOG 0534)
-
Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer RTOG 0815

Renal/Urothelial
Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients with Advanced/Metastatic Urothelial Carcinoma
-
A Phase 1b Study of LY573636-sodium in Combination with Sunitinib Malate in Patients with Metastatic Renal Cell Cancer

Brain
Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma (RTOG 0825)

Esophageal
A Phase III Trial Evaluating The Addition Of Cetuximab To Paclitaxel, Cisplatin, And Radiation For Patients With Esophageal Cancer Who Are Treated Without Surgery (RTOG 0436)

Liver
Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with SorafeNib (GIDEON) Registry trial
-
A Randomized Discontinuation Study of XL184 in Subjects with Advanced Solid Tumors: no more than one prior stnd trtmt, HCC that has been diagnosed by core biopsy or CT/MRI including angiography and serum level AFP > 400 ng/mL in subjects with liver cirrhosis and/or chronic viral hepatitis B or C infection

Hematology
A phase III, open label, randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia
-
An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma

Endometrial/Ovarian
A PHASE III TRIAL OF PELVIC RADIATION THERAPY VERSUS VAGINAL CUFF BRACHYTHERAPY FOLLOWED BY PACLITAXEL/CARBOPLATIN IN PATIENTS WITH HIGH-RISK, EARLY STAGE ENDOMETRIAL CANCER GOG 0249

Phase I
A Phase I Open Label, Multicenter, Dose-Escalation Study to Determine the Maximum Tolerated Dose (MTD), Dose Limiting Toxicity (DLT), Safety and Pharmacokinetics of PG-11047 when Used in Individual Combinations with 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients with Advanced Solid Tumors or Lymphoma
-
A Phase 1b, Multicenter, Dose-Escalation Study of LY573636-sodium in Combination with 1) Gemcitabine HCl or 2) Docetaxel or 3) Temozolomide or 4) Cisplatin, or 5) Erlotinib in Patients with Advanced Solid Tumors
-
A Phase 1b Study of LY573636-sodium in Combination with Sunitinib Malate in Patients with Metastatic Renal Cell Cancer
-
A Phase I Safety Study of LY2787106 in Patients with Cancer and Anemia I3S-MC-JABA
Phase 1 and Pharmacologic Study of MM-111 in Combination with Multiple Treatment Regimens in Patients with Advanced HER2 Positive Solid Tumors

Radiation/RTOG
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer  B39 RTOG 0413
-
A Phase III Clinical Trial Comparing Trastuzumab Given Concurently with Radiation and Radiation Alone for Women with Her2-Postive Ductal Carcinoma In Situ (DCIS) Resected by Lumpectomy NSABP B43 RTOG
-
A RANDOMIZED PHASE III COMPARISON OF STANDARD- DOSE (60 Gy) VERSUS HIGHDOSE (74 Gy) CONFORMAL RADIOTHERAPY WITH CONCURRENT AND CONSOLIDATION CARBOPLATIN/PACLITAXEL +/- CETUXIMAB (IND# 103444)IN PATIENTS WITH STAGE IIIA/IIIB NSCLC  RTOG 0617
-
A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy In Prostate Cancer Patients With A Rising Psa After Radical Prostatectomy (RTOG 0534)
-
Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy With or Without Short-Term Androgen Deprivation Therapy for Patients With Intermediate-Risk Prostate Cancer RTOG 0815
-
Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma (RTOG 0825)
-
A Phase III Trial Evaluating The Addition Of Cetuximab To Paclitaxel, Cisplatin, And Radiation For Patients With Esophageal Cancer Who Are Treated Without Surgery (RTOG 0436)
-
A PHASE III TRIAL OF PELVIC RADIATION THERAPY VERSUS VAGINAL CUFF BRACHYTHERAPY FOLLOWED BY PACLITAXEL/CARBOPLATIN IN PATIENTS WITH HIGH-RISK, EARLY STAGE ENDOMETRIAL CANCER GOG 0249

STAR
A randomized,open-label, multi-center phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST)